Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19: A Phase 2 Randomized Controlled Double-Blind Study.

Respiratory failure secondary to COVID-19 is associated with morbidity and mortality. Current anti-inflammatory therapies are effective but are given systemically and have significant side effects. Furosemide has anti-inflammatory properties, can be administered by inhalation, and is inexpensive. We investigated the efficacy of nebulized furosemide as an adjunctive therapy for COVID-19 respiratory failure. A double-blind, randomized, placebo-controlled trial. Multicenter ICU study. Adults requiring invasive mechanical ventilation secondary to COVID-19. Patients were randomized within 48 hours of intubation to receive inhaled furosemide or placebo until day 28, death, or liberation from mechanical ventilation. The study was stopped early due to waning incidence of COVID-19; 39 patients were available for analysis with mean ± sd age of 70.5 (10.8) years, Acute Physiology and Chronic Health Evaluation II 26.1 (7.8) and Fio In this trial of inhaled furosemide for COVID-19 respiratory failure, differences in Pao

Informations de copyright

Copyright © 2024 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine.

Déclaration de conflit d'intérêts

Dr. Muscedere is the scientific director for the Canadian Frailty Network and has received in-kind contributions of endotracheal tubes for a study of the prevention of ventilator-associated pneumonia from N8 Pharma. Dr. Boyd receives a stipend from Ontario Health-Trillium Gift of Life Network for his role as Regional Medical Lead and has received in-kind support from Edwards LifeSciences of cerebral oximeters for the Cerbral Oxygenation and Neurological Outcomes Following Critical Illness-2 study. The remaining authors have no disclosures or conflicts of interest relevant to this work.